Financial Snapshot

Revenue

TTM

$0.00

Gross Margin

Last 4 Quarters

N/A

Net Income

TTM

-$79.68K

Current Assets

Last 4 Quarters

N/A

Current Liabilities

2025 Q3

$242.7K

Current Ratio

Last 4 Quarters

N/A

Total Assets

2025 Q3

$18.04K

Total Liabilities

Last 4 Quarters

N/A

Book Value

Last 4 Quarters

N/A

Cash

2025 Q3

$18.04K

P/E

Last 4 Quarters

N/A

Free Cash Flow

Last 4 Quarters

N/A

Stock Price

Market Cap: $420 Thousand

About

The filing excerpts provided for RDGAD (accession 000141057825000352, filed 2025-03-14) contain only boilerplate SEC cover-page language and do not disclose the company name, business description, revenue model, products, customers, geography, or competitive positioning. No canonical business description can be written from the available evidence.

Source: SEC 10-K, filed 2025-03-14

Industry: Blank Checks Peers: TELIX QSAM INC. Windtree Therapeutics Inc Bellerophon Therapeutics, Inc. BELLICUM PHARMACEUTICALS, INC TuHURA Biosciences Inc BioRestorative Therapies Inc Canton Strategic Holdings Inc Lixte Biotechnology Holdings Inc LogicBio Therapeutics, Inc.